Li Linzhi, Yue Rensong, Zeng Lihong, Wang Shengnan, Zhuo Wuhui, Sun Yingying
Hospital of Chengdu University of Traditional Chinese Medicine.
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Medicine (Baltimore). 2020 Nov 13;99(46):e23011. doi: 10.1097/MD.0000000000023011.
Subacute thyroiditis (SAT) is a transient and self-limiting inflammatory thyroid disease. There is no clear evidence for specific etiology, but it is generally thought to occur after viral infection. Characteristics of SAT include severe pain of the anterior neck, enlarged firm thyroid, disordered thyroid function, elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), typical ultrasound findings (hypoechoic areas) and low thyroid uptake of radioactive iodine or technetium-99 m because of the destructive etiology of the hyperthyroidism. Evidences showed Xiaochaihu decoction (XCHD) has a significant effect on improving the symptoms of SAT patients. The purpose of this study is to assess the safety and effectiveness of XCHD for patients with SAT.
The literature that has been identified via searching 6 Chinese electronic databases and eight English electronic databases from inception to September 21, 2020 will be included in the study. Research selection, data extraction as well as research quality assessment will be completed by 2 experienced researchers independently. The primary outcome is remission rate. Data analysis will be conducted by the RevMan 5 software, and GRADE will help to assess the level of evidence. The heterogeneity of data will be investigated by a heterogeneity x test, as well as the Higgins I test. A subgroup analyses and sensitivity analysis will be conducted to explore the sources of heterogeneity.
The results of this study will be published in a peer-reviewed journal.
This study will draw a conclusion about whether XCHD is safe and effective in treating SAT on the basis of evidence-based medicine. This conclusion will provide areliable scientific evidence for the alternative treatment for the management of SAT. OSF REGISTRATION NUMBER:: https://osf.io/8hbue.
亚急性甲状腺炎（SAT）是一种短暂的自限性甲状腺炎症性疾病。目前尚无明确的特定病因证据，但一般认为其发生于病毒感染后。SAT的特征包括颈部前方严重疼痛、甲状腺肿大坚实、甲状腺功能紊乱、红细胞沉降率（ESR）和C反应蛋白（CRP）升高、典型的超声表现（低回声区）以及由于甲状腺功能亢进的破坏性病因导致甲状腺对放射性碘或锝-99m摄取降低。有证据表明小柴胡汤（XCHD）对改善SAT患者的症状有显著效果。本研究的目的是评估XCHD治疗SAT患者的安全性和有效性。
通过检索6个中文电子数据库和8个英文电子数据库，纳入从数据库建立至2020年9月21日期间的文献。由2名经验丰富的研究人员独立完成研究筛选、数据提取以及研究质量评估。主要结局指标为缓解率。采用RevMan 5软件进行数据分析，GRADE将有助于评估证据水平。通过异质性x检验以及Higgins I检验研究数据的异质性。将进行亚组分析和敏感性分析以探索异质性来源。
本研究结果将发表在同行评审期刊上。
本研究将在循证医学基础上得出XCHD治疗SAT是否安全有效的结论。该结论将为SAT治疗的替代疗法提供可靠的科学证据。开放科学框架注册号：https://osf.io/8hbue 。
